AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00140907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: 25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
Study NCT01032434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: sertraline: 50-200mg/day
Study NCT03645096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 500 mg
Description: Pregnenolone 500 mg capsule.
Study NCT03645096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 800 mg
Description: Pregnenolone 800 mg capsule.
Study NCT03645096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule manufactured to mimic pregnenolone capsule.
Study NCT03588806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xtampza ER (oxycodone)
Description: Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
Study NCT00123162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
Study NCT00123162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single vaginal dose of placebo and monitored for 4 hours.
Study NCT03089333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
Study NCT03089333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
Study NCT03089333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide 5Mg Tablet
Description: Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
Study NCT03089333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide 5Mg Tablet
Description: Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
Study NCT04453358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InCourage-Connect
Description: This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.
Study NCT04453358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InCourage
Description: This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
Study NCT00833963 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Participants will receive trastuzumab as determined by their treating physicians' standards of care.
Study NCT00833963 — intervention group
Intervention type: DRUG
Intervention: Pertuzumab
Description: Participants will receive pertuzumab as determined by their treating physicians' standards of care.
Study NCT00833963 — intervention group
Intervention type: DRUG
Intervention: Ado-Trastuzumab Emtansine
Description: Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
Study NCT02767869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banaba
Description: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
Study NCT02767869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
Study NCT03125031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow adhesive adult/pediatric sensor
Study NCT03125031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow adhesive adult/neonatal sensor
Study NCT00475241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure therapy for PTSD
Description: exposure-based treatment for PTSD
Study NCT00475241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present centered therapy for PTSD
Description: present focused coping and problem solving for PTSD
Study NCT00309166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix vaccine
Description: All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
Study NCT01191801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vosaroxin + cytarabine
Description: Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)
Study NCT01191801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + cytarabine
Description: Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)
Study NCT01380275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Description: This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
Study NCT01380275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
Study NCT00309166 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B vaccine
Description: All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
Study NCT00723983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan succinate
Description: Sumatriptan succinate 50 mg taken orally
Study NCT00723983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 Study Patch
Description: NP101 study patch 4 hour application
Study NCT02034214 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life skills education
Description: The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
Study NCT02034214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life skills education
Description: The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
Study NCT02034214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reproductive health services
Description: All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
Study NCT02034214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reproductive health services
Description: All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
Study NCT02034214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic livelihoods
Description: The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
Study NCT01484197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 µg indacaterol maleate (LB)
Description: 75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
Study NCT02983851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation
Description: Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
Study NCT02983851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive mechanical ventilation
Description: Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
Study NCT01665040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation device implantation
Description: Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan.
Study NCT01484197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 µg indacaterol maleate (PoS)
Description: 75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
Study NCT01484197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 37.5 µg indacaterol maleate (PoS)
Description: 37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
Study NCT01484197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol (LB)
Description: Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
Study NCT00089024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy.
Study NCT03230006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: The UP will be conducted in a standardized fashion, over 16 sessions, following the published therapist guide with minor refinements for application in the proposed comorbid population.
Study NCT03230006 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Take Control
Description: TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
Study NCT02859844 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Tibial Nerve Stimulation (TTNS)
Study NCT02859844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation (TTNS)
Study NCT04075513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine, 300 U/ml
Description: Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection
Study NCT04075513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec, 100U/ml
Description: Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection
Study NCT04075513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Rapid acting insulin analogs
Description: Route of administration: SC injection
Study NCT04075513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy: Rapid acting insulin analogs
Description: Route of administration: SC injection
Study NCT04218214 — intervention group
Intervention type: OTHER
Intervention: LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)
Description: Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
Study NCT03468751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
Study NCT00073736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 300mg/m2/day
Description: 7-day continuous infusion in 28-day cycles
Study NCT00073736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 600 mg/m2/day
Description: 7-day continuous infusion in 28-day cycles
Study NCT00073736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 1200 mg/m2/day
Description: 7-day continuous infusion in 28-day cycles
Study NCT00073736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 1800 mg/m2/day
Description: 7-day continuous infusion in 28-day cycles
Study NCT00073736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133 2400 mg/m2/day
Description: 7-day continuous infusion in 28-day cycles
Study NCT01142778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
Study NCT00089024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 \[negative margins\] or R1 \[positive microscopic margins\]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
Study NCT00089024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
Study NCT01484197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol (PoS)
Description: Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
Study NCT03609632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Glucose
Description: Intake of 75g of glucose with 1g of 13C leucine pre-feeding
Study NCT02254252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: nicorandil (10mg tablets, two times a day)
Study NCT00910832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eductyl suppository
Description: one suppository every morning during 21 days
Study NCT00910832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suppository
Description: placebo suppository every morning during 21 days
Study NCT03681366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISC3.5 plus
Description: The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
Study NCT03488719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 25 MG
Description: A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
Study NCT03488719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 50 MG
Description: A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
Study NCT03488719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate 100 MG
Description: A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
Study NCT03476798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib 600mg PO BID daily
Study NCT03942640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: subctaneous perineural injection
Description: Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection
Study NCT03942640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: deep prolotherapy
Description: The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
Study NCT04540614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises programme
Description: Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
Study NCT04540614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises programme
Description: Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
Study NCT01814449 — intervention group
Intervention type: OTHER
Intervention: 18FMISO PET/CT scan
Description: The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
Study NCT01814449 — intervention group
Intervention type: DRUG
Intervention: Letrozole
Description: Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.